Hiển thị các bài đăng có nhãn Cancer. Hiển thị tất cả bài đăng
Hiển thị các bài đăng có nhãn Cancer. Hiển thị tất cả bài đăng

Thứ Tư, 15 tháng 5, 2013

FDA approves new drug to fight prostate cancer

  • 2013-04-29T082721Z_2_CBRE93S0JBL00_3_BAYER.JPG

German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.

The Food and Drug Administration, which has reviewed Xofigo under its priority program, said on Wednesday the injection is cleared for treatment of bone metastases in men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Bayer licensed Xofigo, also called radium-223 dichloride, from Norway's Algeta in 2009 and the two companies will co-promote the injection in the U.S.

Bayer has also requested approval for the drug in Europe, where it would market the drug alone.

The drug, which according to Bayer could become a "blockbuster" product with annual sales of least 1 billion euros, has some properties of calcium. That makes it cling to cancerous bone cells and then destroy them via alpha rays, which is more targeted than the shotgun approach of conventional radiotherapy.


View the original article here

Thứ Ba, 14 tháng 5, 2013

Angelina Jolie reveals she had preventive double mastectomy after discovering cancer gene

  • angelina hot mama.jpg

    Actress Angelina Jolie arrives at the 68th annual Golden Globe Awards in Beverly Hills, California, January 16, 2011. REUTERS/Mario Anzuoni (UNITED STATES - Tags: ENTERTAINMENT) (GOLDENGLOBES-ARRIVALS) - RTXWNST

Angelina Jolie says she underwent a preventive double mastectomy earlier this year because she carries a gene that increases her risk of developing breast cancer and ovarian cancer.

In a New York Times article published late Monday, Jolie says she carries the "faulty" BRCA1 gene. She writes that the risk of developing cancer varies, but doctors estimated she had an 87 percent risk of breast cancer and a 50 percent risk of ovarian cancer. 

Jolie, whose mother died at age 56 after a long battle with cancer, says she decided to have the preventive mastectomy to be "proactive" for the sake of her six children with her partner, Brad Pitt.

"Today it is possible to find out through a blood test whether you are highly susceptible to breast and ovarian cancer, and then take action," Jolie writes.

Jolie says she began the process on Feb. 2 and it took three months for her to fully recover. She says she is sharing her story to encourage other women who may not be informed about the procedure and their options.

"I wanted to write this to tell other women that the decision to have a mastectomy was not easy," she writes. "But it is one I am very happy that I made. My chances of developing breast cancer have dropped from 87 percent to under 5 percent. I can tell my children that they don’t need to fear they will lose me to breast cancer."

Click for more from the New York Times. 


View the original article here

New approaches give women more options for breast cancer surgery

  • race_komen_050811.jpg

    Shown here is the start of a race to benefit Susan G. Komen for the Cure and another cancer-fighting group in Lyndhurst, Ohio, on May 8.AP

Treating breast cancer almost always involves surgery, and for years the choice was just having the lump or the whole breast removed. Now, new approaches are dramatically changing the way these operations are done, giving women more options, faster treatment, smaller scars, fewer long-term side effects and better cosmetic results.

It has led to a new specialty -- "oncoplastic" surgery -- combining oncology, which focuses on cancer treatment, and plastic surgery to restore appearance.

"Cosmetics is very important" and can help a woman recover psychologically as well as physically, said Dr. Deanna Attai, a Burbank, Calif., surgeon who is on the board of directors of the American Society of Breast Surgeons. Its annual meeting in Chicago earlier this month featured many of these new approaches.

More women are getting chemotherapy or hormone therapy before surgery to shrink large tumors enough to let them have a breast-conserving operation instead of a mastectomy. Fewer lymph nodes are being removed to check for cancer's spread, sparing women painful arm swelling for years afterward.

Newer ways to rebuild breasts have made mastectomy a more appealing option for some women. More of them are getting immediate reconstruction with an implant at the same time the cancer is removed rather than several operations that have been standard for many years. Skin and nipples increasingly are being preserved for more natural results.

Some doctors are experimenting with operating on breast tumors through incisions in the armpit to avoid breast scars. There's even a "Goldilocks" mastectomy for large-breasted women -- not too much or too little removed, and using excess skin to create a "just right" natural implant.

Finally, doctors are testing a way to avoid surgery altogether, destroying small tumors by freezing them with a probe through the skin.

"Breast surgery has become more minimalistic," said Dr. Shawna Willey of Georgetown's Lombardi Comprehensive Cancer Center.

"Women have more options. It's much more complex decision-making."

Breast cancer is the most common cancer in women around the world. In the U.S. alone, about 230,000 new cases are diagnosed each year.

Most can be treated by just having the lump removed, but that requires radiation for weeks afterward to kill any stray cancer cells in the breast, plus frequent mammograms to watch for a recurrence.

Many women don't want the worry or the radiation, and choose mastectomy even though they could have less drastic surgery. Mastectomy rates have been rising. Federal law requires insurers to cover reconstruction for mastectomy patients, and many of the improvements in surgery are aimed at making it less disfiguring.

Here are some of the major trends:

IMMEDIATE RECONSTRUCTION

Doctors used to think it wasn't good to start reconstruction until cancer treatment had ended -- surgery, chemotherapy, radiation. Women would have a mastectomy, which usually involves taking the skin and the nipple along with all the breast tissue, followed by operations months later to rebuild the breast.

Reconstruction can use tissue from the back or belly, or an implant. The first operation often is to place a tissue expander, a balloon-like device that's gradually inflated to stretch the remaining skin and make room for the implant. A few months later, a second surgery is done to remove the expander and place the implant. Once that heals, a third operation is done to make a new nipple, followed by tattooing to make an areola, the darkened ring around it.

The new trend is immediate reconstruction, with the first steps started at the time of the mastectomy, either to place a tissue expander or an implant. In some cases, the whole thing can be done in one operation.

Nationally, about 25 to 30 percent of women get immediate reconstruction. At the Mayo Clinic, about half do, and at Georgetown, it's about 80 percent.

SPARING SKIN, NIPPLES

Doctors usually take the skin when they do a mastectomy to make sure they leave no cancer behind. But in the last decade they increasingly have left the skin in certain women with favorable tumor characteristics. Attai compares it to removing the inside of an orange while leaving the peel intact.

"We have learned over time that you can save skin" in many patients, Willey said. "Every single study has shown that it's safe."

Now they're going the next step: preserving the nipple, which is even more at risk of being involved in cancer than the skin is. Only about 5 percent of women get this now, but eligibility could be expanded if it proves safe. The breast surgery society has a registry on nipple-sparing mastectomies that will track such women for 10 years.

"You really have to pick patients carefully," because no one wants to compromise cancer control for cosmetic reasons, Attai said.

"The preliminary data are that nipple-sparing is quite good," but studies haven't been long enough to know for sure, Willey said. "It makes a huge difference in the cosmetic outcome. That makes the woman's breast recognizable to her."

Dr. Judy Boughey, a breast surgeon at the Mayo Clinic, said the new approach even has swayed patients' treatment choices.

"We're seeing women choosing the more invasive surgery, choosing the mastectomy," because of doctors' willingness to spare skin and nipples, she said.

It helped persuade Rose Ragona, a 51-year-old operations supervisor at O'Hare Airport in Chicago. She had both breasts removed on April 19 with the most modern approach: Immediate reconstruction, with preservation of her skin and nipples.

"To wake up and just see your breasts there helped me immensely," she said.

She chose to have both breasts removed to avoid radiation and future worry.

"I felt it was a safer road to go," she said. "I can't live the rest of my life in fear. Every time there's a lump I'm going to worry."

FREEZING TUMORS

Attai, the California breast surgeon, is one of the researchers in a national study testing cryoablation. The technique uses a probe cooled with liquid nitrogen that turns tumors into ice balls of dead tissue that's gradually absorbed by the body. This has been done since 2004 for benign breast tumors and the clinical trial is aimed at seeing if it's safe for cancer treatment.

"The technology is amazing. This is done in the office under local anesthesia, a little skin puncture," Attai said.

In the study, women still have surgery at some point after the freezing treatment to make sure all the cancer is destroyed. If it proves safe and effective, it could eliminate surgery for certain cancer patients.

"I'd love to see the day when we can offer women with small breast tumors a completely non-operative approach, and I do think that's coming soon," Attai said.


View the original article here

Thứ Ba, 7 tháng 5, 2013

Skin Cancer Awareness Month: How to detect and prevent this deadly disease

Skin cancer affects people of all ages and races, and it most often develops on the areas of a person’s skin most exposed to the sun.  It is the most common form of cancer diagnosed in the U.S., with more than 3.5 million diagnoses annually.  According to the American Cancer Society, skin cancer diagnoses equal more than the new diagnoses of breast, prostate, lung and colon cancers combined.  

There are three major types of skin cancer: basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma.  BCC is the most common form of skin cancer and most often occurs on the most sun-exposed areas of your body (i.e. face and neck).  It often appears as a pearly or waxy bump, or a flat, flesh-colored or brown scar-like lesion.  SCC also often occurs on sun-exposed areas of your body, but it presents as a firm, red nodule or a flat, scaly or crusty lesion.  

Melanoma, on the other hand, can develop anywhere on your body – even on skin that is not often exposed to the sun.  In men, it most commonly appears on the trunk, head or neck – and in women, the lower legs.  It often presents as a large brown spot with dark speckles; a mole that changes color, size or texture; a small lesion with irregular borders; or dark lesions on your palms, fingertips, soles or toes.  It is from these signs that the “ABCDEs of Melanoma” were developed:

A: Asymmetry of the mole.  If you were to draw a line across the mole, the two halves will be very different.

B: Borders of the mole are uneven.

C: Color varies throughout the mole.  This can include different shades of brown, tan, black or even red, blue or another color.

D: Diameter of the mole is greater than 6 millimeters (or the size of a pencil eraser); melanomas tend to be larger than benign moles.

E: Evolution of the mole, in size, shape, color, and texture can be indicative of melanoma.

It is estimated that one in five Americans will develop skin cancer, so the chance of you or someone you know developing skin cancer is more real than you may think.  Fortunately, there are some easy tips to help prevent skin cancer.  

First, wear at least SPF 30 sunscreen and protective clothing (e.g. long sleeve shirts, pants, wide-brimmed hats, sunglasses, etc.) every day – even on cloudy days.  Reapply your sunscreen every two to three hours, especially if you are swimming or sweating.  Seek shade during the sun’s harshest hours: between 10 a.m. and 4 p.m.  

Second, avoid tanning, tanning beds and sun burns.  Also, be watchful for any new or changing spots on your skin.  If you do see any spots that are new, have changed, are itchy or are bleeding, see your dermatologist immediately. Not all changes are caused by skin cancer, but it’s always best to speak with your dermatologist.  Early detection affords you the greatest likelihood of successful treatment.

Dr. David B. Samadi is the Vice Chairman of the Department of Urology and Chief of Robotics and Minimally Invasive Surgery at the Mount Sinai School of Medicine in New York City. He is a board-certified urologist, specializing in the diagnosis and treatment of urological disease, with a focus on robotic prostate cancer treatments. To learn more please visit his websites RoboticOncology.com and SMART-surgery.com. Find Dr. Samadi on Facebook.


View the original article here

Boy who created superheroes dies of cancer

A 12-year-old cancer patient from Pennsylvania who invented his own superheroes and published a comic book based on their exploits has died.

The Express-Times newspaper of Easton reports that Zachi Telesha died at his Allentown home after a five-year struggle with bone cancer.

Zachi dreamed up a crime-fighting team called Hero Inc. With help from his school and employees from publisher Rodale, he published the 32-page comic "Hero Up!" last year. Proceeds from the sale of the book go to nonprofit Angel 34 which supports pediatric cancer patients.

The sixth-grader said in an interview a few weeks before his death that regular people can do a little every day to make the world a better place.

Zachi's parents and principal are calling him resilient and inspirational.


View the original article here

Thứ Tư, 1 tháng 5, 2013

Female smokers have a higher colon cancer risk

  • SmokingCigarette

Most people understand the link between smoking and lung cancer, but researchers are learning even casual smokers are increasing their risk for other cancer types as well.

Case in point: Smoking increases the risk for developing colorectal cancer, and female smokers may have a greater risk than male smokers, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Dr. Inger Torhild Gram, professor in the Department of Community Medicine at the University of Tromsø in Norway, wanted to know why the number of new colon cancer cases per year has exploded during the last 50 years for men and women.

During her study she and her colleagues found startling new evidence to suggest women who smoke less than men still get more colon cancer.

“The finding that women who smoke even a moderate number of cigarettes daily have an increased risk for colon cancer will account for a substantial number of new cases because colon cancer is such a common disease,” said Gram in a written statement.

Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the United States, according to the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. About 72 percent of cases arise in the colon and about 28 percent in the rectum.
___________________________________________________
More From EmpowHER:
Despite your Age, It’s Never Too Late To Quit Smoking

National Cancer Report: Fewer Dying, But News isn’t All Good

Women Smokers Have Higher Risk of Squamous Cell Skin Cancer
___________________________________________________

“A causal relationship between smoking and colorectal cancer has recently been established by the International Agency for Research on Cancer of the World Health Organization, but unfortunately, this is not yet common knowledge, neither among health personnel nor the public,” she said.

The American Cancer Society estimates that 142,820 people will be diagnosed with colon cancer in 2013 and that 50,830 will die from colon cancer in the United States.

It’s important to note that while colorectal cancer can be extremely deadly, it’s also one of the most preventable cancer types.

If everyone who is 50 years old or older were regularly screened for colorectal cancer, as many as 60 percent of deaths from this cancer could be avoided, according to the NCI.

To examine the association between cigarette smoking and colon cancer, by tumor location, Gram and her colleagues looked at data for a large Norwegian study of more than 600,000 men and women.

The participants from four surveys initiated by the National Health Screening Service of the Norwegian Institute of Public Health had a short health exam and completed questionnaires about smoking habits, physical activity and other lifestyle factors.

The participants were followed by linkage to the Cancer Registry of Norway and the Central Population Register. During an average 14 years of follow-up, close to 4,000 new colon cancer cases were diagnosed.

Gram and her colleagues found, for the first time, that female smokers had a 19 percent increased risk compared with never-smokers, while male smokers had an 8 percent increased risk compared with never-smokers.

In addition, women who started smoking when they were 16 or younger and women who had smoked for 40 years or more had a substantially increased risk, by about 50 percent.

The study also show the number of cigarettes smoked per day, number of years smoked and number of pack-years smoked increased a woman’s colon cancer risk more than men.


View the original article here

Chủ Nhật, 7 tháng 4, 2013

New breast cancer drug prolongs life

Fifty-year-old Lisa Canale has been battling breast cancer for 15 years – and although she lives with the diagnosis daily, she said she feels great. 

It’s partly due to a new drug she’s been taking called Kadcyla, which was  approved by the U.S. Food and Drug Administration in February.

Kadcyla is a groundbreaking new treatment that targets tumor cells, while sparing healthy ones – helping patients live nearly six months longer.

“A good way to explain this would be if I am trying to turn off one particular light on the ceiling, I'd have to turn off all the lights. But with this drug we can go to one specific light and treat it,” said Dr. Marc Citron, director of cancer services at ProHealth Care Associates.

Citron said that this drug may offer advantages over older medications, because it delays the progression of cancer by several months.

It also delivers more medication, with less side-effects – which is a huge benefit for breast cancer patients like Canales.

“This medication is wonderful, because it gives me the opportunity to do all the things that I need to do. And I just don't have time not to feel well, because I have an active and involved 16-year-old,” said Canales.

For now, the drug is approved for patients who have advanced, metastatic breast cancer that is “HER-2 positive”, and who have also been treated with the drug Herceptin® (trastuzumab), as well as with taxane chemotherapy.

Doctors hope that the drug will be used more widely to fight breast cancer in the future.

“The drug is being investigated for earlier stages of breast cancer, for patients before surgery, (and) for patients right after surgery. Generally, when drugs are effective, for advanced disease, they're even more effective for earlier stages of disease,” Citron said.

For more information, talk to your doctor, or go to Kadcyla.com


View the original article here

Thứ Năm, 4 tháng 4, 2013

Film critic Roger Ebert loses battle with cancer- VIDEO: Remembering Roger Ebert

Roger Ebert, the most famous and most popular film reviewer of his time who become the first journalist to win a Pulitzer Prize for movie criticism and, on his long-running TV program, wielded the nation's most influential thumb, died Thursday, the Chicago Sun-Times reported. He was 70.

Ebert had been a film critic for the Chicago Sun-Times since 1967. He had announced on his blog Wednesday that he was undergoing radiation treatment after a recurrence of cancer.

He had no grand theories or special agendas, but millions recognized the chatty, heavy-set man with wavy hair and horn-rimmed glasses. Above all, they followed the thumb — pointing up or down. It was the main logo of the televised shows Ebert co-hosted, first with the late Gene Siskel of the rival Chicago Tribune and — after Siskel's death in 1999 — with his Sun-Times colleague, Richard Roeper. Although criticized as gimmicky and simplistic, a "two thumbs up" accolade was sure to find its way into the advertising for the movie in question.

Despite his power with the movie-going public, Ebert wrote in his 2011 autobiography "Life Itself," that he considered himself "beneath everything else a fan."

"I have seen untold numbers of movies and forgotten most of them, I hope, but I remember those worth remembering, and they are all on the same shelf in my mind," Ebert wrote in his 2011 memoir, "Life Itself."

He was teased for years about his weight, but the jokes stopped abruptly when Ebert lost portions of his jaw and the ability to speak, eat and drink after cancer surgeries in 2006. But he overcame his health problems to resume writing full-time and eventually even returned to television. In addition to his work for the Sun-Times, Ebert became a prolific user of social media, connecting with fans on Facebook and Twitter.

The thumb logo remained the property of Ebert and Siskel's widow, and in early 2011, Ebert launched his new show, "Ebert Presents At the Movies." The show had new hosts, but featured Ebert in his own segment, "Roger's Office." He used a chin prosthesis and enlisted voice-over guests to read his reviews.

While some called Ebert a brave inspiration, he told The Associated Press in an email in January 2011 that bravery and courage "have little to do with it."

"You play the cards you're dealt," Ebert wrote. "What's your choice? I have no pain, I enjoy life, and why should I complain?"

Ebert joined the Sun-Times part time in 1966 while pursuing graduate study at the University of Chicago, and got the reviewing job the following year. His reviews were eventually syndicated to several hundred other newspapers, collected in books and repeated on innumerable websites, which would have made him one of the most influential film critics in the nation even without his television fame.

His 1975 Pulitzer for distinguished criticism was the first, and one of only three, given to a film reviewer since the category was created in 1970. In 2005, he received another honor when he became the first critic to have a star on the Hollywood Walk of Fame.

Ebert's breezy and quotable style, as well as his knowledge of film technique and the business side of the industry, made him an almost instant success.

He soon began doing interviews and profiles of notable actors and directors in addition to his film reviews — celebrating such legends as Alfred Hitchcock, John Wayne and Robert Mitchum and offering words of encouragement for then-newcomer Martin Scorsese.

In 1969, he took a leave of absence from the Sun-Times to write the screenplay for "Beyond the Valley of the Dolls." The movie got an "X'' rating and became somewhat of a cult film.

Ebert's television career began the year he won the Pulitzer, first on WTTW-TV, the Chicago PBS station, then nationwide on PBS and later on several commercial syndication services. Ebert and Siskel even trademarked the "two thumbs up" phrase.

And while the pair may have sparred on air, they were close off camera. Siskel's daughters were flower girls when Ebert married his wife, Chaz, in 1992.

"He's in my mind almost every day," Ebert wrote in his autobiography. "He became less like a friend than like a brother."

Ebert was also an author, writing more than 20 books that included two volumes of essays on classic movies and the popular "I Hated, Hated, Hated This Movie," a collection of some of his most scathing reviews.

The son of a union electrician who worked at the University of Illinois' Urbana-Champaign campus, Roger Joseph Ebert was born in Urbana on June 18, 1942. The love of journalism, as well as of movies, came early. Ebert covered high school sports for a local paper at age 15 while also writing and editing his own science fiction fan magazine.

He attended the university and was editor of the student newspaper. After his graduation in 1964, he spent a year on scholarship at the University of Cape Town in South Africa and then began work toward a doctorate in English at the University of Chicago.

Ebert's hometown embraced the film critic, hosting the annual Ebertfest film festival and placing a plaque at his childhood home.

Ebert also was embraced online in the years after he lost his physical voice. He kept up a Facebook page, a Twitter account with nearly 600,000 followers and a blog, Roger Ebert's Journal.

The Internet was where he forged relationships with his readers, posting links to stories he found interesting and writing long pieces on varied topics, not just film criticism. He interacted with readers in the comments sections and liked to post old black-and-white photos of Hollywood stars and ask readers to guess who they were.

"My blog became my voice, my outlet, my 'social media' in a way I couldn't have dreamed of," Ebert wrote in his memoir. "Most people choose to write a blog. I needed to."

Ebert wrote in 2010 that he did not fear death because he didn't believe there was anything "on the other side of death to fear."

"I was perfectly content before I was born, and I think of death as the same state," he wrote. "I am grateful for the gifts of intelligence, love, wonder and laughter. You can't say it wasn't interesting."


View the original article here

Understanding thyroid cancer

The butterfly-shaped thyroid gland, in the front of one's neck beneath the voice box, produces hormones that regulates how the body uses energy. In 2012, thyroid cancer will cause approximately 1,780 deaths (1,000 women, 780 men). There will also be 56,460 new cases of the disease (43,21 in women, 13,250 in men), according to the American Cancer Society.

The thyroid creates two hormones: Thyroid hormone and calcitonin. Thyroid hormone affects your heart rate and blood pressure. Calcitonin maintains a healthy level of calcium for the body.

Causes
Cancer occurs when abnormal cells multiply haphazardly, amassing into a malignant tumor. When cancer begins in the thyroid, it is usually one of two kinds; papillary carcinoma (accounts for eight of every ten cases) and follicular carcinoma (accounts for one of every ten cases). Other, less common types include hürthle cell carcinoma, medullary thyroid carcinoma and anaplastic carcinoma.

The disease is three times more likely to afflict women. Low-iodine diets and radiation exposure may increase the likelihood of thyroid cancer.

Symptoms
Mario Skugor, an endocrinologist at the Cleveland Clinic, reports that typical thyroid cancer presents itself as a painless mass in the lower neck. Other possible warning signs of include pain in the neck, difficulty swallowing, a perpetual cold, breathing difficulties, swelling in the neck and vocal hoarseness, reports the American Cancer Society.

Diagnosis
In order to properly diagnose thyroid cancer, one must undergo a physical examination, blood tests and biopsy. During the exam, a physician feels the patient's thyroid for lumps and the surrounding area for lymph nodes.The blood tests check for irregular levels of the thyroid-stimulating hormone. The biopsy is the definitive way to determine the existence of cancer. A surgeon removes a sample of thyroid tissue for a pathologist to examine.

Imaging tests (MRI scan, ultrasound, CT scan, X-ray, nuclear medicine scan) can help with staging the cancer. They generate pictures of the thyroid that illuminate the existence or absence of cancerous cells throughout the body. Sometimes, the doctor may administer a whole body scan after putting a small amount of radioactive iodine into the bloodstream. Cancer cells absorb the iodine, which is visible when scanned.

Treatment
The majority of thyroid cancers are curable, reports the Mayo Clinic. Thyroid cancer treatment depends on the disease's stage and type. A surgeon may perform a  thyroidectomy to remove all or most of the thyroid through an incision in the neck. Often the surgeon will also remove swollen lymph nodes from the neck.

The patient will need to take thyroid hormone medication for the remainder of his or her life, to supply the hormone the thyroid usually produces and to squelch the production of thyroid-stimulating hormone.

After surgery, the patient often takes radioactive iodine capsules, which target the remaining thyroid tissue and seek out lingering cancer cells.

Other common therapies include traditional radiation therapy and chemotherapy, which use high-power X-rays and drugs, respectively.

Amy Y. Chen, surgeon and otolaryngology professor at Emory University School of Medicine, said, "Rarely, a pharyngectomy, esophagectomy, or laryngectomy are necessary if there is invasion of the thyroid cancer to surrounding structures."

For more information, visit the Thyroid Cancer Survivor's Association and the American Thyroid Association.


View the original article here

Thứ Năm, 28 tháng 3, 2013

New gene markers detected for 3 types of cancer

  • DNA strand.jpg

    A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute to Reuters on May 15, 2012. REUTERS/National Human Genome Research Institute/Handout

New research has nearly doubled the number of genetic variations implicated in breast, prostate and ovarian cancer, offering fresh avenues for screening at-risk patients and, potentially, developing better drugs.

The bumper haul of 74 gene changes that can increase risks for the three hormone-related cancers, announced by scientists on Wednesday, is the result of the largest ever study of its kind.

It follows an international project to analyze the DNA of more than 200,000 people - half of them with cancer and half from the general population - to find alterations that are more common in individuals with the disease.

Although each gene variation increases cancer risk by only a small amount, scientists calculate that the 1 percent of men carrying lots of the alterations could have a 50 percent increased risk of developing prostate cancer.

Women with multiple variants could see their risk of breast cancer increase by 30 percent.

Doug Easton of the University of Cambridge, one of the cancer researchers who led the work, said the batch of new genetic discoveries meant medical experts would be able to develop new cancer screening programs.

This will take time, since more research is needed to develop diagnostic tools.

"I would think that within five to 10 years this might be being used commonly, if not in a very widespread population base," said Paul Pharoah, also of the University of Cambridge.

Initially, the additional screening is likely to be targeted at patients with established cancer risk factors, such as carriers of BRCA gene faults. Women with BRCA faults are known to be at greater risk of developing breast and ovarian cancer.

New drugs

Ros Eeles of Britain's Institute of Cancer Research, an expert in prostate cancer, said the new findings were the biggest leap forward yet in understanding the genetic basis of the disease.

"They allow us, for the first time, to identify men who have a very high risk of developing prostate cancer during their lifetime through inheritance of multiple risk genetic variants," she said.

In the case of prostate cancer, scientists found 23 new genetic variations - known as single nucleotide polymorphisms, or SNPs - taking the total to 78. Significantly, 16 were linked with the more aggressive forms of the disease.

For breast cancer the researchers found 49 new SNPs, more than doubling the number previously identified, and in ovarian cancer the tally was 11.

A few of the variations were common to more than one cancer type, suggesting there may be common mechanisms of action that could be targeted by new drugs.

Developing medicines using the insight gained by the latest research will take many years, even assuming that drugmakers can produce compounds that work effectively. Encouragingly, though, companies such as Roche, the market leader in cancer, are getting better at making drugs that apply biochemical "brakes" to tumor cells.

The scientists stressed that genes, while important, were just one side of a complex mix of factors leading to cancer.

"Lifestyle and environmental risks act in concert with the genetics. It is not one or the other - it is always both together," Pharoah told reporters.

The new research was published in a series of papers in Nature Genetics, Nature Communications, PLOS Genetics, the American Journal of Human Genetics and Human Molecular Genetics.


View the original article here

Scientists find treatment to kill every kind of cancer tumor

  • 061012_anhq_cancerdrug_640.jpg

Researchers might have found the Holy Grail in the war against cancer, a miracle drug that has killed every kind of cancer tumor it has come in contact with, the New York Post reported.

The drug works by blocking a protein called CD47 that is essentially a "do not eat" signal to the body's immune system, according to Science Magazine.

This protein is produced in healthy blood cells, but researchers at Stanford University found that cancer cells produced an inordinate amount of the protein thus tricking the immune system into not destroying the harmful cells.

With this observation in mind, the researchers built an antibody that blocked cancer's CD47 so that the body's immune system attacked the dangerous cells.

So far, researchers have used the antibody in mice with human breast, ovary, colon, bladder, brain, liver and prostate tumors transplanted into them. In each of the cases the antibody forced the mice's immune system to kill the cancer cells.

Click for more from the New York Post. 


View the original article here

New genetic testing for prostate cancer may reduce unnecessary treatment

  • DNA genes formatted.jpg

Many studies have found the Prostate-Specific Antigen (PSA) test – the standard exam for prostate cancer – to be a unreliable screening method.   Fortunately, a new report from the New York Times detailed how many more sophisticated prostate cancer tests will soon be on the market.

One such test involves mapping the genome of the cancer itself, in an attempt to distinguish between the most dangerous of tumors and the ones that are slow-growing and do not pose as much of a health risk.  The current PSA test is not very accurate in differentiating between the two, often highlighting tumors that don’t need to be treated.  

The United States Preventive Services Task Force actually recommended against the screening in late 2011, saying more men were harmed through unnecessary biopsies than men who were saved from dying of cancer.

“It’s not that screening doesn’t work; it’s that we haven’t done a great job of targeting treatments for the tumors that need it,” Dr. Matthew R. Cooperberg, an assistant professor of urology at the University of California, San Francisco, told the New York Times.

PSA tests work by measuring the amount of PSA – a protein produced by the prostate gland – in the blood.  The new genetic testing would look for more than just the PSA protein, mapping multiple genes in the prostate, as well as other biological markers.

Two test developers, Genomic Health and Myriad Genetics, have created screening tests that analyze the genes of prostate cancers after biopsy, allowing doctors to gauge just how serious the tumor is.  While the tests may come at a high price – maybe more than $3,000 – the companies say it could potentially reduce spending for unnecessary treatments by nearly $12 million, according to the New York Times.

According to Genomic Health, the company’s test – called the Genomic Prostate Score – will go on sale after Genomic Health releases supporting data on the test at the American Urological Association’s annual meeting in May.  

Myriad Genetics conducted a study on its test, called Prolaris, which was published last year in the British Journal of Cancer.  The research found that 19 percent of men with low-risk scores from the Prolaris test die from prostate cancer within 10 years, as opposed to 75 percent of men with high-risk test scores.

Myriad Genetics’ test has been available since last year, but sales of the product have remained low.  Some doctors are still skeptical that genetic testing is the way to go, because they maintain these tests have yet to be adequately substantiated.  Also, many men who test positive for prostate cancer still wish to receive treatment, even if they are recommended to forgo it based on their low test scores.

However, some experts believe these tests are the step in the right direction.

“Even if we can only convince 15 to 20 percent of men that we have enough confidence that they don’t need to be treated, that will be a big step forward,” Dr. Eric A. Klein of the Cleveland Clinic, who has worked with Genomic Health, told the New York Times.

Click for more from the New York Times.


View the original article here

Thứ Ba, 26 tháng 3, 2013

Soy tied to better lung cancer survival among women

  • Tofu

Women with lung cancer who ate the most soy before their diagnosis might live a little longer than those who ate the least, according to a new study.

Of 444 Chinese women with lung cancer, researchers found those who consumed the most soy milk, tofu and similar products were 7 to 8 percent less likely to die over a 13-year period, compared to women who ate an average amount of soy.

"To our knowledge this is the first study to suggest this association. Although this finding is promising, it would be premature to make any recommendation based on the findings of a single study," said Dr. Gong Yang, the study's lead author from Vanderbilt University School of Medicine in Nashville, Tennessee.

Another study from Yang's group published last year found women who ate the most soy were less likely to develop lung cancer in the first place.

"Based on that study, we hypothesized people with a history of eating a lot of soy food - if they're diagnosed with lung cancer, their lung cancer would be less aggressive," he said.

Laboratory and animal research has also suggested phytoestrogens - plant-based estrogens similar to those produced by women's ovaries, which are present in soy - can prevent tumor cells from spreading.

According to the researchers, only 15 percent of U.S. women who develop lung cancer are still alive five years after their diagnosis. So any improvement in survival could be meaningful.

For the new study, the researchers used information from the Shanghai Women's Health Study, which began in 1997 and surveys 75,000 women every two to three years.

Between 1997 and 2010, 444 women in the study developed lung cancer, and 318 of them died. They were - on average - 66 years old at diagnosis, and 92 percent of them had never smoked.

Before the women were diagnosed, they had eaten an average of 16 grams of soy from food each day, according to diet questionnaires.

The researchers found women who consumed more than that - 21 to 31 g of soy per day - were about seven to 8 percent less likely to die during the study, compared to women who ate 16 g daily.

On the other hand, women who only ate about 6 g of soy per day were over 40 percent more likely to die during that time.

"This longitudinal follow-up study provides the first evidence that soy food consumption before cancer diagnosis may favorably affect clinical outcomes of lung cancer in women," the researchers wrote in the Journal of Clinical Oncology on Monday.

But Matthew Schabath, a lung cancer researcher who was not involved with the new study, stressed that it can't prove eating soy prevents people with lung cancer from dying.

For example, Schabath, from the Moffitt Cancer Center in Tampa, Florida, told Reuters Health women who eat a lot of soy may be in better health to begin with, and would be expected to live longer than women in poorer health.

Researchers also said more studies on soy and lung cancer are needed to confirm the findings.

"We need to take it with a grain of salt until this data is validated in clinic trials," Schabath said.


View the original article here

Chủ Nhật, 17 tháng 3, 2013

Brooke Burke-Charvet: How I beat cancer

  • 660_BrookeBurke.jpg

You'd never guess looking at her now, laughing over lunch at an outdoor restaurant in Malibu, Calif., but just four months ago Brooke Burke-Charvet was undergoing treatment for thyroid cancer. 

The only sign of her ordeal? She's wearing a Steri-Strip bandage over the scar on her neck—and she eventually throws a big hat on to protect it from the sun.

The diagnosis was a shock for the 41-year-old Dancing With the Stars co-host. After all, life has been good! Newly married to David Charvet, the mom of four (daughters Neriah, 13, and Sierra, 11, from a previous marriage, and daughter Rain, 6, and son Shaya, 5, with Charvet) was busy juggling her career and blended family when, last spring, her doctor found a lump. Ten biopsies later, she scheduled surgery. She credits a routine checkup with finding her cancer early, and exercise with helping her bounce back (she is now cancer-free).

"I need to move. I need to sweat and get that adrenaline rush. It's the best antidepressant."

- Brooke Burke-Charvet

Burke-Charvet sat down with Health to explain how she stayed strong through her diagnosis and treatment.

Your cancer was caught as a result of a routine physical, right?

Yep, it was a regular checkup. The reason I went public about it was to spread the word about preventive health. I book that long, annoying, yearly physical, even when I feel perfectly fine. Do we really want to carve out half the day for that? No, but it's so important.

My regular doctor, Robert Huizenga, MD—he's actually a doctor on The Biggest Loser—is very thorough. He noticed an extremely questionable, tiny little thing, and he was like, 'This might be nothing; I still want you to get an ultrasound.' And the nodule was large enough that it required a biopsy. The next doctor said, 'We can't determine if it's benign or malignant, so you can come back in six months and get another ultrasound. Or you can get a second opinion.' Which is what I did. I got a second and a third opinion. I want to say this delicately, but doctors are human beings. In the end, I had 10 biopsies."

What was it like when you first heard you needed surgery?

It just didn't hit me. It was 8 in the morning, and I was standing in the kitchen, and I get the call, and I was like, "OK, I'll call you next week." And he was like, "No, don't call me next week. We need you to have surgery now."

What was your treatment after surgery?

My nodule was encapsulated, the surrounding tissue was good and it wasn't in my lymph nodes. So I didn't have to take radioactive iodine, thank God. After a thyroidectomy, most people have to start taking a synthetic thyroid pill, because your thyroid is gone. But for 10 years I've had Hashimoto's disease, which is when your thyroid is not functioning properly, so I'd already been taking Synthroid.

What was the hardest part of this experience for you?

My family's having to deal with it. My oldest daughter was really worried. My middle daughter, Sierra, was a bit more scientific. And my youngest kids were a little nervous. When you have a medical issue, the whole family goes through it. But thank God it's over. Over and done.

Have you changed anything since your diagnosis?

"I was already eating healthy. But it really confirms how good I feel when I work out. After lying around for a few weeks, I was like, 'Agh! I need to move. I need to sweat and get that adrenaline rush.' It's the best antidepressant. It's like the best medicine in the world."

This article originally appeared on Health.com. 


View the original article here

Thứ Sáu, 15 tháng 3, 2013

High-fat dairy may increase risk of death from breast cancer relapse

  • Whole milk istock.jpg

After a patient has been diagnosed and treated with breast cancer, the types of food she consumes may have a significant impact on her long-term survival.

A new study has revealed women who consume higher rates of high-fat dairy products after a breast cancer diagnosis have a much greater chance of dying from recurrence of the disease years later.  The research, conducted by scientists at Kaiser Permanente in Oakland, Calif., is published in the Journal of the National Cancer Institute.

The idea to examine breast cancer prognosis in relation to dairy consumption stems from the way milk and dairy are produced in Western culture.

“The way milk and dairy are produced in the western world, through breeding of cows and modification of feed, cows are able to give milk at the same time as being pregnant,” lead author Dr. Candyce Kroenke, staff scientist with the Kaiser Permanente Division of Research, told FoxNews.com. “This leads to higher estrogen rates in the fats of the milk.”

Kroenke said while estrogen resides in the fats of milk regardless, pregnant cows have higher estrogen rates, therefore the milk they produce have much higher rates of estrogen stored in the fat.  In nature, pregnant cows are not capable of producing milk until after their calves are born.

While high-fat dairy products made in Western society are generally high in estrogen, dairy products in which the fat was removed – such as skim milk or 1 and 2 percent milk – had effectively lower estrogen levels.

For women who have been diagnosed with breast cancer, higher amounts of estrogen in the body can trigger relapse of the disease.  Therefore, Kroenke and her team theorized that the more high-fat dairy a woman consumed, the higher her chances for breast cancer relapse – and ultimately death.

To test their hypothesis, the researchers followed a cohort of 1,893 women who had been diagnosed with breast cancer approximately two years prior to the beginning of the study.   Each participant was given a food-frequency questionnaire, and 1,513 were given a follow-up questionnaire six years later. Overall, the participants were followed for an average of 12 years.

In the questionnaire, the women were asked about their dairy intake – such as milk, yogurt, butter and cheese.  They were also asked what kinds of milk they consumed, whether it was high-fat, 1 or 2 percent, or non-fat.  With the answers of those questions, the researchers were able to categorize each woman into either a high-fat dairy group or a low-fat dairy group.

“In terms of total dairy intake, we didn’t find a strong association overall,” Kroenke said.  “But for women who consumed high levels of high-fat dairy, they had an elevated risk of breast cancer death and death from all causes, as well as non-breast cancer-related deaths.  For the non-breast cancer-related deaths, the women died primarily of cardiovascular disease.”

Of the sample of women, 349 had breast cancer recurrence and 372 died of any cause, 189 of them from breast cancer.  This translated to a 50 percent elevated risk of dying from breast cancer for women who consumed high-fat dairy.

With such a substantial association established, Kroenke noted a very clear take-away message from the research.

“Overall, one of the potential opportunities is to shift away from using high-fat dairy towards using lower fat dairy sources,” Kroenke said.  “Also, women with breast cancer can reduce their dairy intake, or people can shift to more plant-based milks.  Those are some of the recommendations.”

The study has the influence to potentially change dairy production in Western society, and we could return to a more natural process – more as a consequence of pregnancy rather than genetically designed to occur during pregnancy, Kroenke said.  However, she said this transformation will not occur until profit-gain is no longer the main priority of the dairy industry.

“Obviously in a different food environment, high-fat dairy may not be as much of an issue,” Kroenke said.


View the original article here

Thứ Tư, 13 tháng 3, 2013

Woman removes colon to prevent deadly cancer

By the time she was 34, Lynne Fisher had already experienced incredible tragedy.

Her uncle Charlie had died at the age of 33, followed by her father a year later at the age of 47.  More significantly, both of their lives had been claimed by the same disease – colon cancer.

While the episode was very traumatic, a connection between their deaths was never made, until 10 years later when the unthinkable happened.  Fisher’s brother was diagnosed with colon cancer, also called bowel cancer, at the young age of 28 – and passed away two years later.

“My brother Mickey died, which was really traumatic,” Fisher, 51, who lives in Nottingham, England, told FoxNews.com. “I’d seen my uncle, my dad, my brother all die.  And I was really close to my brother; there was only a two-year age gap.  Watching your younger brother die is just horrible.”

Realizing that the family had a connection of some kind, doctors warned Fisher she could possibly develop the disease and that the increased risk was most likely passed down from her father.  However, genetic screening wasn’t available then, so Fisher, her two brothers and sister started having colonoscopies every three years in order to check for signs of the developing disease.

During this time, Fisher had a small nervous breakdown, feeling that everyone around her was dying of the same disease.  She vowed that if she ever contracted colorectal cancer, she wouldn’t pursue treatment, believing nothing could be done to save her, and that she should try to enjoy the time she had left.

Then in 2006, 13 years after Mickey’s death, Fisher’s older brother Clive was diagnosed with colon cancer at the age of 38.

“While he was in the hospital, he had lots of tests, and they told him he had a mutated gene that runs in our family,” Fisher said. “They explained it to him, and then he rang me and said, ‘They can’t save my life, but Lynne, you should get yourself tested, and then at least you’ll know.’”

Doctors had identified in Clive a faulty gene that is linked to a condition called hereditary nonpolyposis colorectal cancer (HNPCC) – also known as Lynch syndrome.  First discovered by Henry T. Lynch in 1966, Lynch syndrome is one of the most common hereditary causes of colon cancer, causing 3 percent of all cases.

People with Lynch syndrome develop polyps – abnormal growths of tissue – in their colons.  However, unlike in individuals without the faulty gene, the progression from a small polyp to full-blown cancer is a lot quicker for these kinds of patients.

“If (the polyps) are removed when they’re small, a lot of patients can keep their colons,” Dr. Anish Sheth, a gastroenterologist at the University Medical Center at Princeton in New Jersey, who did not treat Fisher, told FoxNews.com.   “If you catch it later where the polyps are too big, you have to have surgery and some people will remove the majority of the colon.”

The lifetime risk of someone with Lynch syndrome developing bowel cancer is 70 to 80 percent.

At first, Fisher said she didn’t want to know if she had the gene.

“They gave me lots of options: Did I want to know? What would I do if I did have it?” Fisher said.  “I nearly didn’t want to know, because I thought, ‘What difference would it make?’  But all my family urged me to have the test, and I got the results that I’ve got it.”

According to Sheth, a person with Lynch syndrome can have multiple mutated genes that contribute to the development of cancer.

“They all fit into this category of mismatched repair genes,” Sheth said.  “As our cells are dividing and replicating as we grow, there are just inevitable errors along the way.  There are genes we have that are designed to identify these mistakes and then correct them.  However, these genes which are responsible to repair these mismatches are actually abnormal (in people with Lynch syndrome) , so you get these cells who incorporate all these errors” – ultimately leading to cancer.

Upon the discovery of her genetic mutation, Fisher was presented with a very complicated surgical option.  Her doctor recommended she have a subtotal colectomy, in order to remove a large part of her colon.  He told Fisher he was 100 percent sure she would get bowel cancer if she didn’t have the procedure done.  But initially, Fisher didn’t want it.

“Because no one could save Clive’s life, and no one could save Mickey’s life, so I felt a bit guilty that they could save mine,” Fisher said.

But finally the urgings of her family convinced her to have the surgery – as well as inspiration from one of Fisher’s idols: Sharon Osbourne.  Osbourne announced she had colon cancer in 2002 and had surgery to remove part of her colon.  

“I read a story on Sharon Osbourne – she’s my idol; I have my hair like her,” Fisher said. “Sharon had some colon removed cause of some bowel cancer, and it made me realize that famous people are just normal people.  Just because she’s very famous, she still has these things going on in her family that I’ve got going on in my family, we have similar paths we’re following… So I thought she did it, other people have it, I might as well do it too.”

Surgeons ended up removing a large portion of her colon and reconstructed her small intestine to essentially function as her large intestine.

“My small intestine is sewed onto my rectal stump,” Fisher said.  “Normally you have the colon – well that’s gone.  I haven’t got a bag, but it means when I eat, within half an hour I need to go to the toilet.  And there are lots of things that go through; I don’t digest things as much.”

While she still experiences pain and frequent visits to the hospital, Fisher is thankful she had the surgery, as her risk of developing colon cancer has been decreased to 30 percent.   Also, Fisher is a mother of three, so she also knows her children are at risk of having the mutated gene and they will need to get tested soon.  

Overall, Fisher urges anyone to see a doctor as soon as possible if they have any change in bowel habits – albeit an uncomfortable subject to talk about.

“A doctor has seen lots of things,” Fisher said. “They’re there to save your life, and if you do not go to the hospital and get it checked out – you’re someone’s mom, dad, brother, sister, son, daughter, etc.  There’s someone who doesn’t want to lose you.  It’s important to get yourself checked.”

Fisher is involved with the charity Beating Bowel Cancer, located in England.  To learn more about the charity and how to contribute, visit www.beatingbowelcancer.org.


View the original article here

Dr. Manny: Was Hugo Chavez 'given' cancer? That's ridiculous

Is the world crazy?  When will this stupidity end?

The acting head of state from Venezuela is putting together a Venezuelan medical commission to investigate whether or not Hugo Chávez’s cancer was induced by the United States government.

What a ridiculous idea.  The simple answer to this mystery: it’s impossible to be “given” cancer.

First, we don’t know how long this man has had cancer.  We only have recent reports from the Venezuelan government, so we don’t know if he’s had this cancer for a few months or a decade.

Second, we don’t even know what kind of cancer he had; we only know it was in his pelvis.  So was it prostate cancer? And if that’s the case, how in the world do you give some prostate cancer?

Overall, we know very little about Hugo Chávez’s medical history.  When it comes to our democratically elected presidents, each one is required to get a physical every year and then release the exam’s results to the American public.  In the United States, we are pretty well aware of the health status of our leaders, unlike in socialist environments, which are currently present in Venezuela, Cuba and North Korea.

All we do know is that over the years, there has been a lot of speculation about whether or not Chávez smoked, he was overweight and may have suffered from high blood pressure.  Cancer is a natural biological alteration of cell physiology, which is linked to associated factors like genetics, environmental pollutants and underlying medical conditions.  It is certainly nothing that can be given to you overnight.  

This Venezuelan commission has a better chance of finding life on the moon than coming up with realistic, scientific proof that their former president was poisoned with metastatic cancer.


View the original article here

Chủ Nhật, 10 tháng 3, 2013

Chavez Dies After Battle With Cancer

Venezuela's vice president announced that President Hugo Chavez died on Tuesday, ending 14 years of rule by the firebrand socialist but leaving his party firmly in control of the nation.

Vice President Nicolas Maduro said that Chavez died "after battling a tough illness for nearly two years."

The death apparently sets up a presidential election to replace Chavez, whose illness prevented him from taking the oath of office for the term to which he was re-elected last year.

Under the constitution, the head of Congress, Diosdado Cabello, would assume the interim presidency.

The announcement came just hours after Maduro announced the government had expelled two U.S. diplomats from the country.

Maduro also said "we have no doubt" that Chavez's cancer, which was first diagnosed in June 2011, was induced by foul play by "the historical enemies of our homeland."

He compared the situation to the death of the Palestinian leader Yasser Arafat, claiming Arafat was "inoculated with an illness."

Chavez's inner circle has long claimed the United States was behind a failed 2002 attempt to overthrow him, and he has frequently played the anti-American card to stir up support. Venezuela has been without a U.S. ambassador since July 2010.

Maduro is Chavez's self-anointed successor and has been taking on a larger role since the socialist leader urged Venezuelans to choose him as president before disappearing in early December to undergo a fourth round of cancer surgery in Cuba.

Venezuela's Constitution calls for snap presidential elections to be held if Chavez dies, and some analysts wondered whether Maduro's suggesting the country was under attack by U.S. subterfuge might not be an excuse to delay the election and tighten his grip on power.

The government announced late Monday that Chavez's condition was "very delicate" due to a "new, severe" respiratory infection threw an already anxious nation into even greater uncertainty

"We don't know if he's alive or if he's dead, because they are manipulating the public," Antonio Perez, a retired 60-year-old public servant, said of the government. "Everyone want to just see the president to know if it's true that he's still with us."

Supporters of the 58-year-old president prayed for Chavez on Tuesday at a chapel outside the military hospital where the government says he has been since Feb. 18.

Maduro aired his claim of an alleged attempt to destabilize "Venezuelan society" and the "political system constructed in recent years" before the nation's high command, and the governors of 20 of 23 states loyal to President Chavez, half of them former military officers.

He accused U.S. Embassy's Air Force attache Col. David Delmonaco of spying on Venezuela's military and seeking to involve officers in "destabilizing projects." Maduro gave Delmonaco 24 hours to leave, and U.S. officials said he had already departed the country.

Later Tuesday, Foreign Minister Elias Jaua said a second U.S. Air Force attache was being expelled, also for alleged espionage.

"Let's remember that active participation of the United States in the fascist coup of 2002," Jaua said.

Chavez had neither been seen nor heard from, except for photos released in mid-February, since submitting to a fourth round of surgery in Cuba on Dec. 11 for an unspecified cancer in the pelvic area. It was first diagnosed in June 2011.

The government said Chavez returned home on Feb. 18 and has been confined to Caracas' military hospital ever since.

Maduro said Tuesday that the government was "on the trail of other elements that figure in this entire venomous scenario and are seeking to stir up trouble."

The man Chavez defeated in Oct. 7 presidential elections, the youthful Miranda state Gov. Henrique Capriles, would be expected to represent the opposition in any new elections.

Maduro repeated government claims that Capriles met in the United States over the weekend with right-wing U.S. conspirators and was planning to meet over the weekend with Roberta Jacobsen, assistant U.S. secretary of state for the hemisphere.

One provocateur on state TV even accused the Capriles family of buying a New York City apartment with stolen funds.

Capriles responded via Twitter Tuesday by calling Maduro a liar.

"Lie after lie in every speech," he said.

According to Venezuela's Constitution, elections were to be called if the president could not be sworn in on Jan. 10, but a Supreme Court packed with Chavez loyalists said that wasn't necessary.

The campaigning, though undeclared, has nevertheless already begun. Maduro has frequently commandeered all broadcast channels, Chavez-style, to tout the "revolution" and vilify the opposition.

Chavez has run Venezuela for more than 14 years as a virtual one-man show, gradually placing all state institutions under his personal control. But the former army paratroop commander, who rose to fame by launching a failed 1992 coup, never groomed a successor with his same kind of force of personality.

Maduro said last week that the president had begun receiving chemotherapy around the end of January.

Doctors have said such therapy is not necessarily to beat Chavez's cancer into remission, but could have been palliative, to extend Chavez's life and ease his suffering.

Dr. Carlos Castro, scientific director of the Colombian League Against Cancer, said "it's difficult to predict" when Chavez might die, but he believes "it's a matter of days."

Castro said Chavez could face further respiratory complications if he receives more intense chemotherapy treatment.

If the president's medical team "gives him strong chemotherapy again, then it would not be surprising if some infections reappear," Castro said in a telephone interview.

While in Cuba, Chavez suffered a severe respiratory infection in late December that nearly killed him, Maduro said last week. A tracheal tube was inserted then, and government officials have said his breathing remained labored.

Libardo Rodriguez, a 60-year-old orange juice vendor, said he was very worried after Monday evening's announcement and the government should provide more information about Chavez.

"We are worried because he does not appear. The truth is that I don't know what's happening," said Rodriguez, who identified himself as a Chavez supporter.

"There are many rumors and nobody knows who to believe," he said. "We hope he's alive."


View the original article here

Thứ Hai, 4 tháng 3, 2013

Calcitonin salmon cancer risk appears plausible, FDA staff say

Staff reviewers for the U.S. Food and Drug Administration said that a potential increased risk of cancer with drugs containing calcitonin salmon appears plausible.

In briefing documents released on Friday, the reviewers said the risk raises concerns about the overall risk versus benefit of calcitonin products to treat osteoporosis in postmenopausal women.

Calcitonin products include Novartis AG's Miacalcin injection and nasal spray and Unigene Laboratories Inc's nasal spray. Privately held Upsher Smith Laboratories Inc distributes Unigene's product in the United States. Generic calcitonin products are also available.

Calcitonin salmon is a man-made version of the hormone calcitonin that is found in salmon.

The reviewers said significant questions remain about calcitonin salmon's effectiveness in reducing fractures in the treatment of postmenopausal osteoporosis.

An advisory panel to the FDA is scheduled to discuss the products on March 5 and will make a recommendation to the agency on whether to allow the continued marketing of these products for that use.

Last July European regulators recommended that long-term use of calcitonin be curtailed after a review found evidence of a small increased risk of cancer with long-term use of the drugs.

They recommended that they should only be authorized for short-term use in Paget's disease, a bone disorder; for acute bone loss due to sudden immobilization; and for excess calcium in the blood caused by cancer. They ruled that the benefits of calcitonin-containing medicines did not outweigh their risks in the treatment of osteoporosis and that they should no longer be used for this condition.

Unigene officials declined to comment on the FDA staff review as they do not distribute a calcitonin product in the United States. Upsher Smith officials were not immediately available for comment. Novartis said in a statement that it "places the highest priority on patient safety and the appropriate use of its medicines and is looking forward to the opportunity to engage in the discussion at the upcoming meeting."

Unigene shares were down 20.65 percent at $0.12 on the pink sheets. Novartis shares were up 1 percent.


View the original article here

Thứ Sáu, 1 tháng 3, 2013

Triple Negative Breast Cancer Day raising funds for a cure

A year ago if you asked me if I was able to see myself where I am today, the answer would be no.

On February 29, 2012, I left work early for a mammogram and ultrasound on a mysterious lump in my left breast. I didn’t return to work that day. I was diagnosed with breast cancer at the young age of 30.

Soon after my diagnosis I found out I had triple negative breast cancer, which is negative for three receptors commonly found in tumors such as estrogen, her2 and progesterone. This form of breast cancer is aggressive and disproportionately affects young women under 40, African American women and women who have a genetic mutation called BRCA1, which I have.

Finding out you have this disease is scary and at times, overwhelming. We don't have are many treatment options for other types of breast cancer such as tamoxifen or Herceptin. We have surgery, chemotherapy, radiation and prayer that once in remission, it never returns.

Every 30 minutes, a woman is diagnosed with triple negative breast cancer. The Triple Negative Breast Cancer Foundation works feverishly to make sure no woman who is diagnosed with triple negative breast cancer is alone – and is raising funds to work towards a cure. One way is through a grassroots movement to raise funds called Triple Negative Breast Cancer Day which is on March 3, 2013.

“The TNBC Foundation is launching the inaugural Triple Negative Breast Cancer Day on March 3, 2013.  Our goal is to use this day to expand our national footprint while making an impression on health care providers, scientists, policy-makers and patients across the country,” said Hayley Dinerman, Acting Executive Director of the Triple Negative Breast Cancer Foundation.

"At the Triple Negative Breast Cancer Foundation, our only focus is to walk with triple negative breast cancer patients in all that they go through, as we energize the scientific community to find a break through," said Dinerman.

There are many ways to get involved. TNBC Day has local events all across the country, now until March 3. I am one of its champions, which is a group of women who are helping organize the events, pitch ideas and create fundraising pages. To learn more, please visit www.tnbcfoundation.org.

Today I am in remission and have completed all my treatment. It was a really tough year, but undoubtedly the support I received from TNBC Foundation has helped me through every step. I am proud to work with the Foundation to raise money for research for a cure and make sure no young woman ever has to be scared or feel alone when faced with this diagnosis.

Annie Goodman is a producer for "Your World With Neil Cavuto" at Fox News Channel in New York City. Look for more articles and updates from Annie on her survival from triple negative breast cancer on FoxNewsHealth.com. You can follow Annie on Twitter at @annieg917


View the original article here